Menopur (Menotrophin)

Menotrophin contains both FSH and LH activity. After injection, the hormones bind to their specific ovarian receptors, activating signaling pathways that promote granulosa and theca cell proliferation, estradiol production, and maturation of ovarian follicles leading to ovulation.

The dose of Menopur is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian response, treatment protocol, and monitoring results. Exact dosing regimens are not standardized and must follow clinical guidance.

Menopur is not intended for use during an established pregnancy and its safety in pregnancy has not been established. Women should avoid conception until treatment is completed and a negative pregnancy test is confirmed. Limited data exist for breastfeeding, so caution is advised and consultation with a healthcare professional is recommended.

To order Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Menopur is a urinary‑derived gonadotropin containing both FSH and LH activity, whereas many alternatives are recombinant FSH‑only preparations. The combined activity can be advantageous in certain protocols, but dosing flexibility and purity differ. Choice of product depends on clinician preference, patient response, and specific treatment goals.

Menopur must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once reconstituted, use the solution promptly according to the manufacturer’s instructions and discard any unused portion after the recommended time.

Menopur is supplied as an injectable solution for subcutaneous or intramuscular injection. The vial is reconstituted with the appropriate diluent, drawn into a sterile syringe, and administered according to the dosing schedule prescribed by the treating physician, typically once daily during the stimulation phase.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause severe abdominal pain, fluid accumulation, and thromboembolic events; multiple pregnancy, increasing obstetric complications; and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these complications.

Menopur is contraindicated in individuals with known hypersensitivity to menotrophin or any excipients, in women who are already pregnant, and in patients with uncontrolled thyroid disease, active ovarian cysts, or severe ovarian failure. Caution is also advised for those with a history of severe OHSS.